share_log

药石科技(300725.SZ):目前暂未涉及CRISPR基因编辑相关业务

Pharmaceutical Stone Technology (300725.SZ): Currently not involved in CRISPR gene editing related business

Gelonghui Finance ·  Nov 24, 2023 01:43

Gelonghui November 24丨Pharmaceutical Stone Technology (300725.SZ) stated on the investor interactive platform that the company is currently not involved in CRISPR gene editing related business. The company closely followed various innovative technologies in the field of targeted protein degradation (TPD), designed and developed novel CRBN ligands using the company's unique master molecular blocks, and promoted them to the market, which received good feedback. The company has also provided API synthesis process development and production services, formulation process development and production services for a number of targeted protein degradation chimeric projects. Some projects have already entered clinical phase I and phase II.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment